nach oben

Der Nervenarzt

Erschienen in:

01.02.2010 | Übersichten

Impfen und Multiple Sklerose

verfasst von: Dr. M. Löbermann, A. Winkelmann, E.C. Reisinger, U.K. Zettl

Erschienen in: Der Nervenarzt | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Wie bei anderen chronisch-entzündlichen Erkrankungen sind Impfungen zum Schutz vor Infektionskrankheiten auch bei Patienten mit Multipler Sklerose (MS) von großer Bedeutung, denn bakterielle und virale Infekte können MS-Schübe auslösen. Berichte über eine mögliche Progression der Erkrankung durch einzelne Impfungen haben zu einer generellen Zurückhaltung vor Schutzimpfungen auf Seiten der betroffenen Patienten und der behandelnden Ärzte geführt. Für die meisten Impfstoffe sind Studien bekannt, die das Risiko bei Patienten mit MS untersucht haben. Einige Impfungen, wie die Gelbfieberimpfung, können bei MS nicht empfohlen werden. Tetanus- oder Hepatitis-B-Impfungen dagegen stellen nach aktuellem Kenntnisstand keinen Risikofaktor für die Entstehung oder Progression einer MS dar. Vor und während einer immunmodulierenden Therapie bei MS-Patienten sollte auf einen ausreichenden Schutz vor impfpräventablen Erkrankungen geachtet werden.

Der vorliegende Beitrag fokussiert einerseits auf die Indikationen und möglichen spezifischen Nebenwirkungen von Impfungen bei MS-Patienten und andererseits auf Probleme, die unter einer immunmodulatorischen Therapie beachtet werden müssen.

Ahlgren C, Odén A, Torén K, Andersen O (2009) Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol Scand 119:313–320CrossRefPubMed

Ascherio A, Zhang SM, Hernán MA et al (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344:327–332CrossRefPubMed

Baumhackl U, Franta C, Retzl J et al (2003) A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 21 [Suppl 1]:56–61

Bogdanos DP, Mieli-Vergani G, Vergani D (2000) Virus, liver and autoimmunity. Dig Liver Dis 32:440–446CrossRefPubMed

Buljevac D, Flach HZ, Hop WC et al (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125:952–960CrossRefPubMed

Briggs WA, Rozek RJ, Migdal SD (1980) Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. Ann Intern Med 92:471–477PubMed

British Society of Rheumatology (2002) Vaccinations in the immunocompromised person: Guidelines for the patient taking immunosuppressants, steroid and the new biological therapies. Online: http://www.rheumatology.org.uk/guidelines/guidelines_other/vaccinations [18.06.09]

Cao M, Sasaki O, Yamada A et al (1992) Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine 10:238–242CrossRefPubMed

Center for Disease Control and Prevention (CDC) (2002) Adverse events associated with 17D-derived yellow fever vaccination – United States, 2001–2002. MMWR Morb Mortal Wkly Rep 51(44):989–993

10.

Confavreux C, Suissa S, Saddier P et al (2001) Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 344:319–326CrossRefPubMed

11.

Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67:652–659CrossRefPubMed

12.

Davies K, Woo P (2002) Immunization in rheumatic diseases of childhood: an audit of the clinical practice of british paediatric rheumatology group members and a review of the evidence. Rheumatology 41:937–941CrossRefPubMed

13.

De Keyser J (1998) Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection 26:319CrossRef

14.

De Keyser J, Zwanikken C, Boon M (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159:51–53CrossRef

15.

Dengler TJ, Strnad N, Zimmermann R et al (1996) Pneumokokkenimpfung nach Herz- und Lebertransplantation – Immunantworten bei immunsupprimierten Patienten und gesunden Kontrollpersonen. Dtsch Med Wochenschr 121:1519–1525CrossRefPubMed

16.

DeStefano F, Verstraeten T, Chen RT (2002) Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines 1:461–466CrossRefPubMed

17.

DeStefano F, Verstraeten T, Jackson LA et al (2003) Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60:504–509CrossRefPubMed

18.

Erlanger TE, Weiss S, Keiser J et al (2009) Past, present, and future of Japanese encephalitis. Emerg Infect Dis 15(1):1–7CrossRefPubMed

19.

Flachenecker P, Toyka KV, Hartung HP (1995) Aktive Schutzimpfungen bei multipler Sklerose. Dtsch Med Wochenschr 120(44):1513–1516CrossRefPubMed

20.

Fraser A, Goldberg E, Acosta CJ et al (2007) Vaccines for preventing typhoid fever. Cochrane Database Syst Rev (3):CD001261

21.

Fujinami RS, Oldstone MB (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230:1043–1045CrossRefPubMed

22.

Gelinck L, Teng Y, Rimmelzwaan G et al (2007) Poor serological response upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66 [Suppl II]:160 (Abstr THU0116)

23.

Glück T, Müller-Ladner U (2008) Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 46(9):1459–1465CrossRefPubMed

24.

Gold R, Barreto L, Ferro S et al (2007) Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol 18:241–248PubMed

25.

Gout O (2001) Vaccinations and multiple sclerosis. Neurol Sci 22:151–154CrossRefPubMed

26.

Hemmer CJ, Littmann M, Loebermann M et al (2005) Ein Fall von FSME in Mecklenburg-Vorpommern. Dtsch Med Wochenschr 130:2507–2510CrossRefPubMed

27.

Hernán MA, Alonso A, Hernández-Díaz S (2006) Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 67(2):212–225CrossRefPubMed

28.

Jefferson T, Heijbel H (2001) Demyelinating disease and hepatitis B vaccination: is there a link? Drug Saf 24:249–254CrossRefPubMed

29.

Koerner I, Kochs G, Kalinke U et al (2007) Protective role of beta interferon in host defense against influenza A virus. J Virol 81:2025–2030CrossRefPubMed

30.

Koff RS (1999) The case for routine childhood vaccination against hepatitis A. N Engl J Med 340:644–645CrossRefPubMed

31.

Krueger JG, Ochs HD, Patel P et al (2008) Effect of therapeutic integrin (CD11a) blockade with Efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 128:2615–2624CrossRefPubMed

32.

Kuwert E, Klosterkötter W, Linzenmeier G (1968) Neurological complications following rabies vaccination. Med Klin 63:1326–1328PubMed

33.

Laribière A, Miremont-Salamé G, Reyre H et al (2005) Surveillance of adverse effects during a vaccination campaign against meningitis C. Eur J Clin Pharmacol 61:907–911CrossRefPubMed

34.

Leroux-Roels I, Bernhard R, Gérard P et al (2008) Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3:e1665CrossRefPubMed

35.

Leroux-Roels I, Borkowski A, Vanwolleghem T et al (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580–589CrossRefPubMed

36.

Loebermann M, Kollaritsch H, Ziegler T et al (2004) A randomized, open-lable study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther 26:1084–1091CrossRefPubMed

37.

Maya R, Gershwin ME, Shoenfeld Y (2008) Hepatitis B Virus (HBV) and Autoimmune Disease. Clin Rev Allergy Immunol 34:85–102CrossRefPubMed

38.

Matsui M, Kakigi R, Watanabe S, Kuroda Y (1996) Recurrent demyelinating transverse myelitis in a high titer HBs-antigen carrier. J Neurol Sci 139:235–237CrossRefPubMed

39.

Mäkelä A, Nuorti JP, Peltola H (2002) Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 110:957–963CrossRefPubMed

40.

Merelli E, Casoni F (2000) Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurol Sci 21(4) [Suppl 2]:853–856

41.

Michielsens B, Wilms G, Marchal G, Carton H (1990) Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur Neurol 30:258–259CrossRefPubMed

42.

Mikaeloff Y, Caridade G, Assi S et al (2007) Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 130:1105–1110CrossRefPubMed

43.

Mikaeloff Y, Caridade G, Rossier M et al (2007) Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 161:1176–1182CrossRefPubMed

44.

Miller AE, Morgante LA, Buchwald LY et al (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48:312–314PubMed

45.

Miller H, Cendrowski W, Shapira K (1967) Multiple sclerosis and vaccination. Br Med J 2:210–213CrossRefPubMed

46.

Mokhtarian F, Shirazian D, Morgante L et al (1997) Influenza virus vaccination of patients with multiple sclerosis. Mult Scler 3:243–247CrossRefPubMed

47.

Monteyne P, André FE (2000) Is there a causal link between hepatitis B vaccination and multiple sclerosis? Vaccine 18:1994–2001CrossRefPubMed

48.

Moriabadi NF, Niewiesk S, Kruse N et al (2001) Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56:938–943PubMed

49.

Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV et al (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255(10):1449–1463CrossRef

50.

Myers LW, Ellison GW, Lucia M et al (1977) Swine influenza virus vaccination in patients with multiple sclerosis. J Infect Dis 136:S546–S554PubMed

51.

Piyasirisilp S, Hemachudha T (2002) Neurological adverse events associated with vaccination. Curr Opin Neurol 15:333–338CrossRefPubMed

52.

Plotkin SA, Wiktor T (1978) Rabies vaccination. Annu Rev Med 29:583–591CrossRefPubMed

53.

Oren S, Mendelboim M, Brawn Y et al (2007) Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response. Ann Rheum Dis 66 [Suppl II]:363 (Abstr FRI0275)

54.

Quast U, Herder C, Zwisler O (1991) Vaccination of patients with encephalomyelitis disseminata. Vaccine 9:228–230CrossRefPubMed

55.

Rieckmann P, Moriabadi N, Flachenecker P, Toyka K (2001) Anmerkung zum Beitrag von In: Zipp F, Wandinger KP (Hrsg) Aktuelle Empfehlungen zu Impfungen bei Multipler Sklerose. Nervenarzt 72(12):972CrossRefPubMed

56.

Rieckmann P, Toyka KV, Multiple Sclerosis Therapy Consensus Group (2002) Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, Nervenarzt 73(6):556–563

57.

Ristori G, Buzzi MG, Sabatini U et al (1999) Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology 53:1588–1589PubMed

58.

RKI (2002) Zur Situation bei wichtigen Infektionskrankheiten Impfpräventable Krankheiten in Deutschland bis zum Jahr 2000. Epidemiol Bull 7:49–57

59.

RKI (2007) Fünfjahresinzidenz der Frühsommer-Meningoenzephalitis in Kreisen und Kreisregionen, Deutschland, 2002 bis 2006. Epidemiol Bull 15

60.

RKI (2008) Tetanus: Zwei Fallberichte zu Erkrankungen. Epidemiol Bull 24:193–196

61.

Ross RT, Cheang M (1997) Common infectious diseases in a population with low multiple sclerosis and varicella occurrence. J Clin Epidemiol 50:337–339CrossRefPubMed

62.

Ross RT, Nicolle LE, Cheang M (1997) The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. J Clin Epidemiol 50(1):63–68CrossRefPubMed

63.

Rutschmann OT, McCrory DC, Matchar DB (2002) Immunization Panel of Multiple sclerosis Council for Clinical Practice Guidelines. Immunization and MS: a summary of published evidence and recommendations. Neurology 59:1837–1843PubMed

64.

Sadovnick AD, Scheifele DW (2000) School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 355:549–550CrossRefPubMed

65.

Salvetti M, Pisani A, Bastianello S et al (1995) Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 242:143–146CrossRefPubMed

66.

Sanchez-Fructuoso AI, Prats D, Naranjo P et al (2000) Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols. Transplantation 69(3):436–439CrossRefPubMed

67.

Schattenfroh C (2004) Akute demyelinisierende Enzephalomyelitis nach aktiver Immunisierung gegen Frühsommer-Meningoencephalitits. Nervenarzt 75:776–779CrossRefPubMed

68.

Schattner A (2005) Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23:3876–3886CrossRefPubMed

69.

Schwid SR, Decker MD, Lopez-Bresnahan M for the Rebif Influenza Vaccine Study Investigators (2005) Immune response to influenza vaccine is maintained in patients with MS receiving interferon-beta 1a. Neurology 65(12):1964–1466CrossRefPubMed

70.

Shoenfeld Y, Aron-Maor A (2000) Vaccination and autoimmunity-’vaccinosis’: a dangerous liaison? J Autoimmun 14:1–10CrossRefPubMed

71.

Sibley WA, Bamford CR, Laguna JF (1976) Influenza vaccination in patients with multiple sclerosis. JAMA 236:1965–1966CrossRefPubMed

72.

Sibley WA, Foley JM (1965) Infection and immunization in multiple sclerosis. Ann N Y Acad Sci 122:457–466PubMedCrossRef

73.

Shah I (2008) Acute demyelinating encephalomyelitis due to neural antirabies vaccine. J Travel Med 15:58–59CrossRefPubMed

74.

STIKO (2007) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2007. Epidemiol Bull 30:268–286

75.

Süss J, Schrader C, Falk U, Wohanka N (2004) Tick-borne encephalitis (TBE) in Germany – epidemiological data, development of risk areas and virus prevalence in field-collected ticks and in ticks removed from humans. Int J Med Microbiol 293 [Suppl 37]:69–79

76.

Sutton I, Lahoria R, Tan I et al (2009) CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15:116–119CrossRefPubMed

77.

Tauber E, Kollaritsch H, von Sonnenburg F et al (2008) Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 198(4):493–499CrossRefPubMed

78.

Touzé E, Fourrier A, Rue-Fenouche C et al (2002) Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 21:180–186CrossRefPubMed

79.

Van Damme P, Minervini G, Liss CL et al (2009) Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Hum Vaccin 5(2):92–97CrossRef

80.

Van der Kolk LE, Baars JW, Prins MH et al (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100(6):2257–2259

81.

Veit O, Niedrig M, Chapuis-Taillard C et al (2009) Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48(5):659–666CrossRefPubMed

82.

Versluis DJ, Beyer WE, Masurel N et al (1986) Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 42(4):376–379CrossRefPubMed

83.

Verstraeten T, Davis R, DeStefano F (2005) Immunity to tetanus is protective against the development of multiple sclerosis. Med Hypotheses 65:966–969CrossRefPubMed

84.

Wagner D, Wagenbreth I, Stachan-Kunstyr R et al (1994) Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2 and S gene products. Clin Invest 72:350–352

85.

Wenzel HH, Jahnel J, Hoegenauer C et al (2003) Inadequately low antibodies against the tick-borne encephalitis virus in immunized patients with inflammatory bowel disease and azathioprine treatment. Dig Dis Week Abstr S 1375

86.

WHO (2008) Cumulative number of confirmed human cases of avian influenza A/(H5N1) Reported to WHO, 19 June 2008. Online: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_06_19/en/index.html [01.09.2008]

87.

WHO (2009) Vaccines for the new influenza A (H1N1). Online: http://www.who.int/csr/disease/swineflu/frequently_asked_questions/vaccine_preparedness/en/index.html [20.06.2009]

88.

Wormser GP (2005) Prevention of Lyme borreliosis. Wien Klin Wochenschr 117:385–391CrossRefPubMed

89.

Wu J, Fang HH, Chen JT et al (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48:1087–1095CrossRefPubMed

90.

Wucherpfennig KW (2001) Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108:1097–1104PubMed

91.

Zipp F, Wandinger KP (2001) Aktuelle Empfehlungen zu Impfungen bei Multipler Sklerose. Nervenarzt 72(10):802–806CrossRefPubMed

92.

Zipp F, Weil JG, Einhäupl KM (1999) No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5:964–965CrossRefPubMed

93.

Zuckerman JN (2006) Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78:169–177CrossRefPubMed

Titel: Impfen und Multiple Sklerose
verfasst von: Dr. M. Löbermann
A. Winkelmann
E.C. Reisinger
U.K. Zettl
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 2/2010
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-009-2865-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Impfen und Multiple Sklerose

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Mitteilungen der DGPPN 2/2010

Vaskulitis des Nervensystems bei Infektionserkrankungen

Abrechnung mittels Fallpauschalen beim Hirninfarkt

Meningeosis neoplastica

Morbus Wilson und Multiple Sklerose

Bakterielle Infektionen des Zentralnervensystems

Neu in den Fachgebieten Neurologie und Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko